"RADICAL" FDA REFORM MEASURE WILL NOT PASS CONGRESS THIS YEAR, KENNEDY STAFFER WARNS; SENATE FAVORS BIPARTISAN APPROACH, IMPROVING CURRENT SYSTEM
This article was originally published in The Gray Sheet
FDA reform efforts should focus on improving management within the agency and reducing regulatory burdens on manufacturers to speed product approvals, David Nexon, minority staff director for health for the Senate Labor and Human Resources Committee, said at a Feb. 7 conference in Washington, D.C. hosted by the Progress & Freedom Foundation.
You may also be interested in...
The House Energy & Commerce Committee appears determined to push device reforms through Congress this year, even if Prescription Drug User Fee Act reauthorization does not provide a suitable vehicle
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.